Skip to content

Study · Randomized controlled trial · n = 194 · 2023

2 results

A pilot trial of Thymalfasin (Ta1) to prevent covid-19 infection and morbidities in renal dialysis patients: Preliminary report.

Tuthill CW, Awad A, Parrigon M, Ershler WB

International immunopharmacology2 Mar 2023Cited by 3 (Europe PMC)

PMID36881981 (opens in a new tab)PMCIDPMC9977612 (opens in a new tab)DOI10.1016/j.intimp.2023.109950 (opens in a new tab)PepBankPUB-36881981
Source linkPubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanRandomized controlled trialSafety outcome

    In dialysis patients, 3 deaths occurred in the thymalfasin group compared with 7 in the control group; no statistical test is given.

    In plain wordsIn dialysis patients, fewer deaths were counted with thymalfasin (3) than in the control group (7), without a statistical test.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseDeaths
    Study

    n = 194

    Comparator
    No Ta1 (control group)
    Outcome group
    Mortality · Infection
    Studied dose
    1.6 mg twice weekly · subcutaneous · 8 weeksAs given in this study (human).

    Measurements

    Deaths
    3 count
    Ta1 group
    Deaths
    7 count
    control group

    Source sentences

    Summary
    To date, only 3 deaths have occurred in subjects treated with Ta1 (Group A), compared to 7 in the control (Group B).
    1 context sentence
    Summary · context
    Of these, 194 patients have been randomized 1:1 to either Group A (1.6 mg Ta1 given subcutaneously twice weekly for 8 weeks), or Group B (control group not receiving Ta1).
  2. 02HumanRandomized controlled trialSafety outcome

    In dialysis patients, 5 COVID-19 related serious adverse effects occurred in the thymalfasin group compared with 7 in the control group; no statistical test is given.

    In plain wordsIn dialysis patients, fewer COVID-19 related serious side events were counted with thymalfasin (5) than in the control group (7), without a statistical test.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseCOVID-19 related serious adverse effects
    Study

    n = 194

    Comparator
    No Ta1 (control group)
    Outcome group
    Adverse events · Infection
    Studied dose
    1.6 mg twice weekly · subcutaneous · 8 weeksAs given in this study (human).

    Measurements

    SAEs
    5 count
    Group A (Ta1)
    SAEs
    7 count
    Group B (control)

    Source sentences

    Summary
    There have been 12 COVID-19 related serious adverse effects (SAEs; 5 in Group A, and 7 in Group B).
    1 context sentence
    Summary · context
    Of these, 194 patients have been randomized 1:1 to either Group A (1.6 mg Ta1 given subcutaneously twice weekly for 8 weeks), or Group B (control group not receiving Ta1).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.